Gore excluder device with the C3 delivery system for management of abdominal aortic aneurysm

Cheong J Lee
Mark L Keldahl
Mark D Morasch
Division of Vascular Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

Correspondence to: Mark D Morasch
Division of Vascular Surgery, Northwestern University, 676 North St Clair, Suite 650 Chicago, IL 60611, USA
Tel +1 312 695 2716
Fax +1 312 695 4955
Email mmorasch@nmh.org

Abstract: The GORE Excluder stent-graft is one of the currently available devices approved by the US Food and Drug Administration for use in endovascular aortic repair. Recently, a new delivery system modification has been applied to the Excluder device which allows repositioning of the stent-graft to adjust for accurate proximal landing and facilitate gate cannulation. In this review, we examine the Excluder device with the new C3 delivery system and its potential benefit in the management of abdominal aortic aneurysms.

Keywords: gore excluder, abdominal aortic aneurysm, repair, C3 delivery system

Introduction
Ruptured aneurysm is the 15th leading cause of death in the US, with approximately 15,000 deaths occurring per year. The prevalence of asymptomatic abdominal aortic aneurysm (AAA) in men and women aged >60 years is estimated to be 4%–8% and 0.5%–1.5%, respectively, and is known to increase with age. Open surgical repair to treat AAA has been performed for many years with good outcomes. However, despite advances in technique and perioperative recovery, the procedure still entails significant morbidity to the patient.

Parodi et al were the first to report the use of an endovascular stent-graft for treatment of an AAA in 1991. Twenty years later, endovascular aortic repair has become standard for patients with anatomically suitable AAAs. A number of large, randomized, controlled trials have confirmed that endovascular aortic repair does indeed demonstrate excellent short-term and mid-term outcomes when compared with open repair. However, these studies were based on older generation devices. Endografts have evolved rapidly based on clinical experience and data identifying deficiencies in older models. As such, long-term outcomes of endovascular aortic repair using the current generation devices still need to be examined and defined.

Based on a report from the EUROSTAR registry, all modern stent-grafts perform reasonably well. There is no one device that is clearly superior in short-term and mid-term follow-up. In essence, desirable endovascular aortic repair outcomes are dispersed among the various stent-grafts and the differences in device design and delivery systems allow for individualized graft selection that best suit the patient's specific anatomy.

Excluder stent graft
The Gore Excluder stent-graft (WL Gore and Associates, Flagstaff, AZ), now in its third generation, is one of the currently available endovascular aortic repair devices approved by the US Food and Drug Administration for use in endovascular aortic repair. Recently, a new delivery system modification has been applied to the Excluder device which allows repositioning of the stent-graft to adjust for accurate proximal landing and facilitate gate cannulation. In this review, we examine the Excluder device with the new C3 delivery system and its potential benefit in the management of abdominal aortic aneurysms.
approved by the US Food and Drug Administration. Since its release in 1997, over 112,000 devices have been implanted\(^7\) and numerous studies have demonstrated the efficacy, safety, and durability of the Excluder device.\(^8,9\) Strengths include simplicity in design that employs a flexible, low profile, catheter-mounted delivery system. The device is a modular stent-graft consisting of a bifurcated main body with a single docking limb and assorted iliac limbs and iliac and proximal extension stent-grafts (Figure 1). The Excluder grafts are constructed with expanded polytetrafluoroethylene (ePTFE) and supported by a nitinol stent frame. Barbs are incorporated on the proximal neck of the main body for active infrarenal fixation. These barbs effectively prevent distal stent-graft migration. The main body of the device is constrained in an ePTFE jacket that is stitched with a single strand of ePTFE string. When the string is pulled, the stitches are released, causing a rapid graft deployment of the device in a proximal to distal fashion. The limbs of the Excluder are very flexible and reasonably accommodate complex iliac anatomies.

A number of design improvements to the Excluder have been made over the last decade. One of the most notable changes involved modification of the ePTFE fabric. The original ePTFE microstructure and porosity increased fluid permeation through the device. Aneurysm sac enlargement developed in a subset of patients.\(^10\) This was attributed to endotension. A low porosity Excluder stent-graft was introduced in 2004. The new device added a thin, nonpermeable layer to the ePTFE fabric. Post-marketing clinical studies have demonstrated that addition of the low permeability layer provided for a reduced incidence of sac enlargement when compared with the original version, and the new device was found to be associated with early aneurysm sack shrinkage.\(^11,12\)

A crucial step during device deployment is the accurate placement of the proximal main body in relation to the lowest renal artery orifice. In late 2010, the Excluder device deployment system was modified for the purposes of allowing a more precise and controlled proximal deployment. A unique characteristic of the Excluder device, prior to the modification, had been its rapid deployment mechanism. Although incredibly simple in concept, the accuracy of the “rip-cord” deployment has been contested in the setting of tortuous aortic anatomy. The rapid deployment of a self-expanding device in the setting of angulation and path rotation has resulted in occasional imprecise landing. In these circumstances, the Excluder device tends to land short of the desired target and a proximal extension cuff needs to be placed. While evidence suggests that the original iteration of the Excluder

![Figure 1](https://www.dovepress.com/16949.png)
deployment was highly accurate,13 competing manufacturers have stressed that their systems perform better in that regard by allowing more operator control and precision.

Deemed the C3 delivery system, the new deployment mechanism allows the operator to reposition the Excluder device prior to final release from the delivery catheter up to three times. This is useful in the event that the main body of the Excluder fails to deploy properly, either too high or too low, in relationship to the lowest renal artery. With the C3, the stent-graft main body can be reconstrained following partial deployment, subsequently allowing readjustment of the graft for a more precise proximal landing. This capability may also be useful when gate cannulation proves to be difficult. Simply, if the device position for gate cannulation is unfavorable, the graft can be constrained and rotated into a more favorable position. The Excluder graft itself was unaltered with this delivery system change. Despite its designed application to optimize graft position in hostile aortic neck anatomy, the device IFU did not change with the C3 modification.

C3 delivery system
The C3 delivery system manifold houses the deployment controls as pictured in Figure 2. The outer white casing controls the initial deployment of the proximal trunk of the main body to level of the contralateral gate. When the white outer deployment knob is removed, the constraining mechanism of the device is exposed (transparent handle with a gray turning dial attached at its end). The constraining mechanism controls the closing and reopening of the proximal trunk of the main body. At the time of final device deployment, this constraining mechanism is removed which exposes the final deployment knob. Each component of the C3 deployment system is relatively straightforward to understand and easy to handle. The use of the C3 is outlined below.

Cases proceed in the usual fashion with standard retrograde access of the bilateral common femoral arteries. Once measurements are complete and stiff wires placed, the main body is delivered to position below the lowest renal artery. For initial deployment, the outer white casing of the delivery handle is removed with a 90 degree counterclockwise turn followed by steady, continuous pull (Figure 2A). This maneuver deploys the main body of the device to the level of the contralateral gate. If the proximal position is deemed satisfactory, contralateral gate cannulation can be undertaken at this point. If the main body demonstrates malposition, it can be constrained by turning the gray constraining dial clockwise until the dial stops turning (Figure 2B). Turning the gray constraining dial will move the black nut distally as seen through the transparent knob. This confirms the constraining process. Once the graft is fully constrained, the main body can be moved up or down, and can be rotated to reposition gate location as necessary. Once in satisfactory position, the graft is redeployed by turning the gray constraining dial counterclockwise until the dial stops turning (Figure 2C). The black nut will move proximally to its original position in the transparent knob marked by the black line. The graft is then disengaged from the constraining mechanism by releasing the red safety lock and then pulling the entire transparent knob (Figure 2D and E). To complete deployment to the ipsilateral limb, the inner gray knob is then pulled (Figure 2F).

In the event that deployment of the main body fails, the C3 manifold houses a failure-mode deployment hatch (Figure 3). Located on the main white handle, this hatch can be opened to expose the various wires of the device, including the main body deployment, constraining, and ipsilateral limb deployment wires. Should problems occur, the operator can directly pull the various device wires with a hemostat allowing manual deployment of the endograft at its various stages.

Discussion
Data regarding the Excluder device with the C3 deployment system is limited to a single institution experience reported by Verhoeven et al. In their study, Excluder devices were placed using the C3 deployment system in 25 patients with infrarenal AAA.14 The technical success rate was 100% and operative mortality was zero. The authors used the repositioning capability of the C3 system in 72% of the cases to either achieve better proximal landing or to facilitate cannulation of the contralateral limb. Surprisingly, the majority of the repositioning was performed for gate orientation. The authors concluded that the new deployment system made it possible to reposition the Excluder graft to achieve optimal fixation and sealing. A prospective observational registry is set in place (NCT01398332) for ongoing evaluation of the Excluder with the C3 delivery system.15

Although little is known yet regarding the clinical impact of the C3 delivery system, the long-term cumulative performance with the Excluder graft, which has not been modified, is excellent. Studies have demonstrated very low perioperative morbidity and mortality and excellent protection from aneurysm-related complications.5,9 From the combined cohort analysis (original ePTFE and low permeability grafts) spanning 5 years within the Excluder Phase II trial, the 30-day aneurysm-related death rate was 1.8%. None of
these deaths were actually caused by an aneurysm rupture.\textsuperscript{7} The reintervention rate of the Excluder device was 13.8%, with 72% of these procedures performed within 12 months of initial placement.\textsuperscript{7} With respect to the proximal seal of the graft in situations of severe neck angulation $>60^\circ$, use of the Excluder has resulted in lower reintervention rates when compared with other devices.\textsuperscript{16}

With the performance of the Excluder validated, GORE designed the C3 delivery system to counter the criticisms heaped upon the original “rip-cord” deployment mechanism by changing to a controlled, incremental process. With the original rapid deployment mechanism, the stent-graft deploys from proximal to distal and it opens proximally with a slight expansion of the seam side first (contralateral side).
Operators who are familiar with the Excluder have exploited this tendency to optimize the proximal seal in an angulated infrarenal neck. On the down side, given that the graft does not flower symmetrically, it is subject to jumping, either forward and more often distally, during rapid deployment.

Understandably, the unpredictable mechanical tendencies during rapid deployment can be unnerving for the operator who is unfamiliar with the nuances of the Excluder graft. The ability to reposition the device will be heralded by operators who are relatively new to endovascular aortic repair or those who have limited experience using the Excluder device. In effect, repositioning affords operators “peace of mind” in the setting of suboptimal device positioning, especially when faced with learning to handle a new device.

Guiding a wire through the contralateral gate can also be demanding when the aneurysm is large. Cannulation can also be challenging when the contralateral gate fails to open completely, a significant amount of operative time and resources (e.g., wires, catheters, radiation exposure) may be spent during this process. The ability to adjust the gate based on wire trajectory can improve efficiency. Results of the ongoing prospective observational study on the C3 delivery system may elucidate its impact on operative efficiency.

Designed with the intent of expanding the role of endovascular aortic repair to more hostile neck anatomy, the C3 delivery system could, in effect, increase the number of endovascular aortic repair cases performed outside of device IFU. The Excluder graft’s anatomic suitability criteria, as reported in the device IFU, were not altered with the implementation of the C3 delivery system. Mounting evidence has shown that better outcomes occur when endovascular aortic repair is performed within versus outside of device-specific IFU. Leurs et al demonstrated that a neck length <15 mm was associated with significantly increased rates of early and late proximal type 1 endoleak. Likewise, Hobo et al found that endovascular aortic repair in patients with severe aneurysm neck angulation (>60°) had higher rates of early proximal type 1 endoleak, graft migration, and greater late proximal neck dilatation, and reintervention rates. In a review of their endovascular aortic repair experience, Abruzzese et al stratified patients by IFU status with respect to proximal neck anatomy and found that patients outside IFU experienced higher rates of graft-related adverse events and ultimately a higher rate of perioperative aneurysm-related mortality.

The new C3 deployment system could give clinicians the premise to test the limits of the Excluder IFU, but caution and restraint should be exercised. Historically, graft-related adverse outcomes in cases performed outside IFU may not necessarily be reflective of initial graft positioning, which is the primary endovascular aortic repair variable that the C3 delivery system is designed to control. Unless future data prove otherwise, one should not assume that the use of the Excluder with the C3 delivery system will improve overall outcomes in cases outside of device IFU.

**Conclusion**

As experience with endovascular aortic repair continues to increase, demand from clinicians has spurred innovations in stent-graft device design that enhance performance in challenging aortic anatomy. Gore has implemented the C3 deployment system to improve control and precision during device implantation and build upon their excellent results with the Excluder endograft. Limited evidence does demonstrate improved ease of use, safety, and efficacy with the new device design.

**Disclosure**

MDM receives research support and honoraria for serving as a training course director from WL Gore and Associates Inc.

**References**


